Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P35579
UPID:
MYH9_HUMAN
Alternative names:
Cellular myosin heavy chain, type A; Myosin heavy chain 9; Myosin heavy chain, non-muscle IIa; Non-muscle myosin heavy chain A; Non-muscle myosin heavy chain IIa
Alternative UPACC:
P35579; A8K6E4; O60805; Q60FE2; Q86T83
Background:
Myosin-9, known by alternative names such as Cellular myosin heavy chain, type A, plays a pivotal role in cellular processes including cytokinesis, cell shape, and functions like secretion and capping. It is essential for cortical actin clearance before oocyte exocytosis and promotes cell motility in conjunction with S100A4.
Therapeutic significance:
Myosin-9 is implicated in diseases such as Macrothrombocytopenia with or without nephritis or sensorineural hearing loss, and autosomal dominant Deafness, 17. Understanding the role of Myosin-9 could open doors to potential therapeutic strategies for these conditions.